

=> d his ful

FILE 'REGISTRY' ENTERED AT 10:51:34 ON 30 MAY 2003

E VITAMIN A
E VITAMIN A/CN
L1 2 SEA ABB=ON "VITAMIN A"/CN
E VITAMIN C/CN
L2 1 SEA ABB=ON "VITAMIN C"/CN
E VITAMIN D/CN
L3 1 SEA ABB=ON "VITAMIN D"/CN
E BIOFLAVONOID/CN
E ZINC MONOMETHIONINE/CN
E ZINC METHIONINE/CN
L4 1 SEA ABB=ON "ZINC METHIONINE"/CN
L5 0 SEA ABB=ON L1 AND L2 AND L3 AND L4

FILE 'HCAPLUS' ENTERED AT 10:52:58 ON 30 MAY 2003

L6 37973 SEA ABB=ON (L1 OR ?VITAMIN?(W)A OR ?RETINOL? OR ?FISH?(W)?LIVE
R?(W)OIL?)
L7 92436 SEA ABB=ON (L2 OR ?VITAMIN?(W)C OR ?ASCORBIC?(W)?ACID?)
L8 22688 SEA ABB=ON (L3 OR ?VITAMIN?(W)D)
L9 690 SEA ABB=ON ?BIOFLAVONOID?
L10 175 SEA ABB=ON (L4 OR (?ZINC? OR ZN)(W)?METHIONINE?)
L11 0 SEA ABB=ON L6 AND L7 AND L8 AND L9 AND L10

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO' ENTERED AT
10:57:52 ON 30 MAY 2003

L12 0 SEA ABB=ON L11

FILE 'HCAPLUS' ENTERED AT 11:00:42 ON 30 MAY 2003

L13 12 SEA ABB=ON L6 AND L7 AND L8 AND L9 — *attached*

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO' ENTERED AT
12:27:58 ON 30 MAY 2003

L26 13 SEA ABB=ON L13
L27 13 DUP REMOV L26 (0 DUPLICATES REMOVED) — *attached*

=> d que stat 113

L1 2 SEA FILE=REGISTRY ABB=ON "VITAMIN A"/CN
 L2 1 SEA FILE=REGISTRY ABB=ON "VITAMIN C"/CN
 L3 1 SEA FILE=REGISTRY ABB=ON "VITAMIN D"/CN
 L6 37973 SEA FILE=HCAPLUS ABB=ON (L1 OR ?VITAMIN?(W)A OR ?RETINOL? OR
 ?FISH?(W)?LIVER?(W)OIL?)
 L7 92436 SEA FILE=HCAPLUS ABB=ON (L2 OR ?VITAMIN?(W)C OR ?ASCORBIC?(W)?
 ACID?)
 L8 22688 SEA FILE=HCAPLUS ABB=ON (L3 OR ?VITAMIN?(W)D)
 L9 690 SEA FILE=HCAPLUS ABB=ON ?BIOFLAVONOID?
 L13 12 SEA FILE=HCAPLUS ABB=ON L6 AND L7 AND L8 AND L9

=> d ibib abs hitrn 113 1-12

L13 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:922003 HCAPLUS

DOCUMENT NUMBER: 137:363100

TITLE: Determining the effect of compounds on the ability of
 a subject to control their weight and compositions to
 reduce the effect of such compounds

INVENTOR(S): Buchanan-Baillie-Hamilton, Paula Frances; Peck, Julian
 Claude

PATENT ASSIGNEE(S): UK

SOURCE: Brit. UK Pat. Appl., 89 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2370504	A1	20020703	GB 2001-17052	20010712
PRIORITY APPLN. INFO.: GB 2000-19327			A	20000808

AB A method of detg. the extent of the effect of a target compd. on the
 ability of a test subject to control their wt. The method comprises the
 steps of detg. the degree or severity by which the compd. affects each of
 a plurality of wt. controlling systems present in the subject, detg. the
 persistence of the compd. in the subject and calcg. the effect as a
 function of these values. The effect of target compds. including
 pesticides, environmental pollutants, org. solvents and heavy metals may
 be detd. Wt. controlling systems that may be considered include the
 hormonal system, metab. and muscular activity. A method of detg. the
 effect of an item on the ability of a subject to control their wt.
 comprises detg. the amt. in the item of a plurality of target compds.
 which effect the ability of the subject to control their wt. A method of
 detg. the extent to which a subject has had their ability to control their
 wt. inhibited comprises detg. the amt. in the subject of a plurality of
 compds. which have an effect on the ability of the subject to control
 their wt. Compns. to reduce the effect of one or more target compds.
 present in a subject which effect the ability of the subject to control
 their wt. comprise one or more micronutrients or target compd. absorbants
 which reduce the level of and/or counteract the effect of the target
 compds. The compns. may be used in the treatment of obesity.

IT 50-81-7, Vitamin C, biological studies
 1406-16-2, Vitamin D 11103-57-4,
 Vitamin A
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(wt. control compns. contg.; detg. the effect of compds. on ability of a subject to control their body wt. and compns. to reduce the effect of such compds. in relation to obesity treatment)

L13 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:814673 HCAPLUS

DOCUMENT NUMBER: 137:316098

TITLE: Integrated multi-vitamin and mineral combination for asthma treatment

INVENTOR(S): Benjamin, Samuel D.; Weil, Andrew

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002155163	A1	20021024	US 1999-472669	19991227

PRIORITY APPLN. INFO.: US 1999-472669 19991227

AB A daily multi-vitamin and mineral combination for use in the adjunct care of humans with asthma comprising thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, choline, inositol, p-aminobenzoic acid, **vitamin C**, calcium, magnesium, iodine, selenium, manganese, chromium, molybdenum, boron, zinc, potassium, silicon, sulfur, vanadium, citrus **bioflavonoid** complex, hesperidin complex, rutin, **vitamin A**, **vitamin D**, vitamin E, lycopene, lutein, Coenzyme Q10 and N-acetylcysteine. For adjunct care of humans with diabetes, .alpha.-lipoic acid is substituted for N-acetylcysteine and the amt. of inositol is increased. A method of supplementing the nutritional intake of humans with diabetes and/or asthma through daily oral administration of the appropriate multi-vitamin and mineral combination.

IT 50-81-7, **Vitamin C**, biological studies
68-26-8, **Vitamin A** 1406-16-2,
Vitamin D

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(integrated multi-vitamin and mineral combination for asthma treatment)

L13 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:128881 HCAPLUS

DOCUMENT NUMBER: 136:166454

TITLE: Dietary supplements containing plant-derived chemical substances and their application to health maintenance

INVENTOR(S): Siddiqui, Idrees A.; Dykhhouse, Robin M.; Rehnborg, Sam; Gorenbein, David; Davis, Audrey; Stonebrook, Kerry

PATENT ASSIGNEE(S): Access Business Group LLC, USA

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002051732	A2	20020219	JP 2001-176767	20010612
US 2002025350	A1	20020228	US 2001-878377	20010612
US 6511675	B2	20030128		

PRIORITY APPLN. INFO.: US 2000-210746P P 20000612

AB The dietary supplements contain sulforaphane, naringin, hesperidin, narirutin, quercetin, lutein, lycopene, and isoflavone. The supplements may addnl. contain vitamins and minerals. The supplements prevent disorders due to deficiency of the above substances and enhance effect of biol. antioxidants of humans. The supplements also prevent coronary artery disorders and bone disorders, reduce toxicity of free radicals, and enhance defense system of human bodies.

IT 50-81-7, Vitamin C, biological studies

1406-16-2, Vitamin D 11103-57-4,

Vitamin A

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dietary supplements contg. plant-derived chem. substances, vitamins, and minerals)

L13 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:396664 HCAPLUS

DOCUMENT NUMBER: 134:371827

TITLE: Composition comprising ozonized oils and/or other ozonized natural and/or synthetic products and their use in pharmaceutical, cosmetic, dietetic or food supplement compositions in human and veterinary medicine

INVENTOR(S): Gomez Moraleda, Manuel-antonio; Dall'aglio, Roberto; Melegari, Pierangelo

PATENT ASSIGNEE(S): Spain

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037829	A1	20010531	WO 2000-ES208	20000609

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ES 2162586	A1	20011216	ES 1999-2602	19991125
------------	----	----------	--------------	----------

ES 2162586	B1	20020701		
------------	----	----------	--	--

EP 1273295	A1	20030108	EP 2000-935232	20000609
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

US 2003049333	A1	20030313	US 2002-155472	20020524
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: ES 1999-2602 A 19991125

WO 2000-ES208 W 20000609

AB The compn. comprises (i) one or more ozonized oils and/or natural and/or synthetic ozonized products and (ii) thioctic acid and/or the derivs. thereof, wherein each of the components is present in a concn. ranging from 0.01 to 99.99 by wt. in relation to total wt. and optionally one or more active substances, additives, vehicles or excipients. Said compn. can be used to prep. pharmaceutical, cosmetic, dietetic and food supplement compns. for humans and animals.

IT 50-81-7, Vitamin c, biological studies

1406-16-2, Vitamin d 11103-57-4,

Vitamin a

RL: BUU (Biological use, unclassified); FFD (Food or feed use); PEP

(Physical, engineering or chemical process); RCT (Reactant); THU

(Therapeutic use); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(compn. comprising ozonized oils and/or other ozonized natural and/or synthetic products and their use in pharmaceutical, cosmetic, dietetic or food supplement compns. in human and veterinary medicine)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:265229 HCAPLUS

DOCUMENT NUMBER: 134:285588

TITLE: Pharmaceutical formulation for menopausal women comprising fatty acids, calcium compounds, and folic acid

INVENTOR(S): Levinson, R. Saul; Hermelin, Marc S.; Kirschner, Mitchell I.

PATENT ASSIGNEE(S): KV Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024772	A1	20010412	WO 2000-US23527	20000828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6479545	B1	20021112	US 1999-409059	19990930
EP 1216024	A1	20020626	EP 2000-957857	20000828
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
BR 2000014438	A	20020820	BR 2000-14438	20000828
JP 2003510344	T2	20030318	JP 2001-527771	20000828
US 2002137749	A1	20020926	US 2002-106381	20020327
US 2002173510	A1	20021121	US 2002-131236	20020425
PRIORITY APPLN. INFO.:			US 1999-409059 A	19990930

WO 2000-US23527 W 20000828

AB The present disclosure relates to novel compns. which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms assocd. with menopause, as well as prophylactic effects, and methods for using same. A pharmaceutical compn. contained **vitamin**

A 5000, vitamin D 400, vitamin E 400 IU, vitamin C 100, vitamin B1 20, vitamin B2 20, vitamin B6 25, vitamin B12 50, vitamin B3 100, folic acid 1.0, calcium carbonate 1200, copper 2, zinc 15, DHA/linolenic/linoleic acid 50/25/25 mg, and selenium 65 .mu.g.

IT **50-81-7, Vitamin C, biological studies**

1406-16-2, Vitamin D 11103-57-4,

Vitamin A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).

(pharmaceutical formulation for menopausal women comprising fatty acids, calcium compds., and folic acid)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:706936 HCAPLUS

DOCUMENT NUMBER: 133:265961

TITLE: Nutraceuticals having N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-methyl ester

INVENTOR(S): Ponakala, Subbarao V.; Walters, Gale C.; Gerlat, Paula A.; Hatchwell, Leora C.

PATENT ASSIGNEE(S): The Nutrasweet Company, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057726	A1	20001005	WO 2000-US8210	20000329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-126654P P 19990329

AB The present invention provides nutraceuticals comprising N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester. This invention also provides nutraceuticals comprising a blend of N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester with another sweetener. This invention also provides a method for prepreg. the nutraceuticals of this invention.

IT **50-81-7, Vitamin C, biological studies**

1406-16-2, Vitamin D 11103-57-4,

Provitamin A

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nutraceuticals having N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:464015 HCAPLUS

DOCUMENT NUMBER: 131:106819

TITLE: Vitamin and mineral-containing compositions for the treatment of dry eye

INVENTOR(S): Lalvani, Kartar; Seoane Sanchez, Jose Francisco; Taylor, Robert P.

PATENT ASSIGNEE(S): UK

SOURCE: Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 930072	A1	19990721	EP 1998-300193	19980113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: EP 1998-300193 19980113

AB This invention relates to the use of novel combinations of vitamins and minerals to give a product which affects an improvement in conjunctival goblet cell population d., improving the mucus layer of the tear film to mediate the uniform spread of the aq. phase, and acts to promote an abs. increase in pre-ocular tear film stability in dry eye conditions. The invention involves the systemic use of unique mixts. of specific metallic cations, non-metallic elements and vitamins and provides greater convenience than existing treatments which require the frequent application of topical solns. or lubricant ointments. The action by the invention to improve tear stability is of particular importance to the treatment of dry eye conditions experienced by contact lens users. A compn. for the systemic delivery contained **vitamin A** 300 .mu.g, .beta.-carotene 3, vitamin E 60, **vitamin C** 150 mg, **vitamin D** 2.5 .mu.g, vitamin B6 4.5, vitamin B1 4.5, vitamin B2 7.5, vitamin B12 4.5, folic acid 250, vitamin K1 100 .mu.g, Ca pantothenate 10, Zn 7.5, Fe 3, Cu 1, Mg 50, Mn 2 mg, Se 100, Cr 50, and I 100 .mu.g.

IT 50-81-7, L-Ascorbic acid, biological studies

1406-16-2, Vitamin D 11103-57-4,

Vitamin A

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(systemic delivery compns. contg. vitamins and minerals for treatment of dry eye)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:790367 HCAPLUS

DOCUMENT NUMBER: 130:43343

TITLE: Colostrum-containing nutritional supplement

INVENTOR(S): Anderson, Michael R.; Krauss, Stephen R.
 PATENT ASSIGNEE(S): Creative Labs, Inc., USA
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5846569	A	19981208	US 1997-879954	19970620

PRIORITY APPLN. INFO.: US 1997-879954 19970620

AB A consumable supplement contains a colostrum component composed of processed bovine colostrum, magnesium peroxide as a source of active oxygen, a vitamin such as **vitamin C**, magnesium succinate and a **bioflavonoid**. The colostrum component can be taken sep. or admixed with other minerals, vitamins, etc. In one form, the colostrum component is used as an outer shell for a composite pill, tablet or capsule which includes an inner core contg. one or more vitamins, minerals, enzymes or omega acids in the event that the components of the inner core are incompatible with one or more materials of the colostrum component. Thus, a formulation may contain processed bovine colostrum 100, magnesium peroxide 100, magnesium succinate 30, **vitamin C** 100, and flavonoids 100 mg.

IT 50-81-7, **Vitamin C**, biological studies
 1406-16-2, **Vitamin D** 11103-57-4,
Vitamin A
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (colostrum-contg. nutritional supplement)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:744961 HCAPLUS
 DOCUMENT NUMBER: 130:7433
 TITLE: Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
 INVENTOR(S): Lockett, Curtis
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850051	A1	19981112	WO 1997-US7122	19970505

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG

AU 9729932 A1 19981127 AU 1997-29932 19970505

PRIORITY APPLN. INFO.: WO 1997-US7122 A 19970505

AB A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include **vitamin A**, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, **vitamin C**, **vitamin D**, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus **bioflavonoid** complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below crit. satn. levels, detd. for each individual by carefully monitoring tolerance on titrn. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the prodn. of viable Hb, and alters the overall blood profile. Platelet concn. is increased up to twice that seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manuf. without substantial feedback control by the upper central nervous system.

IT 50-81-7, **Vitamin C**, biological studies

1406-16-2, **Vitamin D** 11103-57-4,

Vitamin A

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of sickle cell disease and treatment of immune system diseases and other diseases normally assocd. with sickle cell anemia with vitamin and mineral and micronutrient formulations in humans)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:163461 HCAPLUS

DOCUMENT NUMBER: 128:208935

TITLE: Multivitamin products useful in achieving autonomic balance

INVENTOR(S): Gonzalez, Nicholas James; Isaacs, Linda Lee

PATENT ASSIGNEE(S): Gonzalez, Nicholas James, USA; Isaacs, Linda Lee

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808522	A1	19980305	WO 1997-US14968	19970826
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,			

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

AU 9741622 A1 19980319 AU 1997-41622 19970826
PRIORITY APPLN. INFO.: US 1996-703301 19960826
 US 1996-744550 19961106
 US 1997-833365 19970404
 WO 1997-US14968 19970826

AB Disclosed are multivitamin products targeted to specific groups. A multivitamin unit dose for balanced carnivore specifications comprises **vitamin A** 1500 IU, vitamin B1 6 mg, vitamin B2 6 mg, niacin 10 mg, niacinamide 30 mg, vitamin B5 45 mg, vitamin B6 6 mg, vitamin B12 90 .mu.g, biotin 21 .mu.g, p-benzoic acid 35 mg, **vitamin C** 50 mg, **vitamin D** 25 IU, vitamin E 50 IU, vitamin K 0.5 mg, folic acid 125 .mu.g, inositol 10 mg, choline 35 mg, .beta.-carotene 825 IU, and **bioflavonoids** 75 mg. Oftentimes, the unit dose is ingested with the aid of water or other liqs.

IT 50-81-7, **Vitamin C**, biological studies
1406-16-2, **Vitamin D** 11103-57-4,
Vitamin A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multivitamin products useful in achieving autonomic balance)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:321923 HCAPLUS
DOCUMENT NUMBER: 126:347291
TITLE: Vitamins and minerals for the treatment of sickle cell disease
INVENTOR(S): Lockett, Curtis G.
PATENT ASSIGNEE(S): Lockett, Curtis G., USA
SOURCE: U.S., 5 pp.
 CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5626884	A	19970506	US 1995-516737	19950818
PRIORITY APPLN. INFO.:			US 1995-516737	19950818

AB A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include **vitamin A**, vitamin B1, vitamin B2, vitamin B6, vitamin B12, **vitamin C**, **vitamin D**, vitamin E, niacinamide, p-aminobenzoic acid, pantothenic acid, choline bitartrate, inositol, rutin, citrus **bioflavonoid** complex, betaine.cntdot.HCl, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below crit. satn. levels, detd. for each individual by carefully monitoring tolerance on titrn. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the prodn. of viable Hb, and alters the overall blood profile. Platelet concn. is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is

achieved by providing sufficient stores of precursors that stimulate low level manuf. without substantial feedback control by the upper central nervous system.

IT 50-81-7, Vitamin C, biological studies

1406-16-2, Vitamin D 11103-57-4,

Vitamin A

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vitamins and minerals for treatment of sickle cell disease)

L13 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:332985 HCAPLUS

DOCUMENT NUMBER: 125:19052

TITLE: Daily vitamin and mineral supplement for women

INVENTOR(S): Sultenfuss, Sherry

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 8 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5514382	A	19960507	US 1994-324780	19941017
PRIORITY APPLN. INFO.:			US 1994-324780	19941017

AB A daily vitamin and mineral supplement for women comprises **vitamin A**, .beta.-carotene, niacin, riboflavin, pantothenic acid, pyridoxine, cyanocobalamin, biotin, p-aminobenzoic acid, inositol, choline, **vitamin C**, **vitamin D**, vitamin E, vitamin K, boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, selenium, zinc and **bioflavonoid**. For women up to 40 yr of age, iron is included. For women over 40 yr of age, iron is optionally included.

IT 50-81-7, Vitamin C, biological studies

1406-16-2, Vitamin D 11103-57-4,

Vitamin A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(daily vitamin and mineral supplement for women)

=> d que stat 113

L1	2	SEA FILE=REGISTRY ABB=ON	"VITAMIN A"/CN
L2	1	SEA FILE=REGISTRY ABB=ON	"VITAMIN C"/CN
L3	1	SEA FILE=REGISTRY ABB=ON	"VITAMIN D"/CN
L6	37973	SEA FILE=HCAPLUS ABB=ON	(L1 OR ?VITAMIN?(W)A OR ?RETINOL? OR ?FISH?(W)?LIVER?(W)OIL?)
L7	92436	SEA FILE=HCAPLUS ABB=ON	(L2 OR ?VITAMIN?(W)C OR ?ASCORBIC?(W)? ACID?)
L8	22688	SEA FILE=HCAPLUS ABB=ON	(L3 OR ?VITAMIN?(W)D)
L9	690	SEA FILE=HCAPLUS ABB=ON	?BIOFLAVONOID?
L13	12	SEA FILE=HCAPLUS ABB=ON	L6 AND L7 AND L8 AND L9

=> d que stat 127

L1 2 SEA FILE=REGISTRY ABB=ON "VITAMIN A"/CN
 L2 1 SEA FILE=REGISTRY ABB=ON "VITAMIN C"/CN
 L3 1 SEA FILE=REGISTRY ABB=ON "VITAMIN D"/CN
 L6 37973 SEA FILE=HCAPLUS ABB=ON (L1 OR ?VITAMIN?(W)A OR ?RETINOL? OR
 ?FISH?(W)?LIVER?(W)OIL?)
 L7 92436 SEA FILE=HCAPLUS ABB=ON (L2 OR ?VITAMIN?(W)C OR ?ASCORBIC?(W)?
 ACID?)
 L8 22688 SEA FILE=HCAPLUS ABB=ON (L3 OR ?VITAMIN?(W)D)
 L9 690 SEA FILE=HCAPLUS ABB=ON ?BIOFLAVONOID?
 L13 12 SEA FILE=HCAPLUS ABB=ON L6 AND L7 AND L8 AND L9
 L26 13 SEA L13
 L27 13 DUP REMOV L26 (0 DUPLICATES REMOVED)

=> d ibib abs 127 1-13

L27 ANSWER 1 OF 13 WPIDS (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 2003-209131 [20] WPIDS
 DOC. NO. CPI: C2003-053172
 TITLE: Multi-vitamin and mineral combination useful for treating
 asthma comprises vitamin B-complex, other B-vitamin,
vitamin C, fat soluble vitamin,
bioflavonoid, carotenoid, phytoestrogen, Coenzyme
 10 and N-acetyl cysteine.
 DERWENT CLASS: B05
 INVENTOR(S): BENJAMIN, S D; WEIL, A
 PATENT ASSIGNEE(S): (BENJ-I) BENJAMIN S D; (WEIL-I) WEIL A
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002155163	A1	20021024	(200320)*		7

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002155163	A1	US 1999-472669	19991227

PRIORITY APPLN. INFO: US 1999-472669 19991227

AN 2003-209131 [20] WPIDS

AB US2002155163 A UPAB: 20030324

NOVELTY - A multi-vitamin, mineral combination comprises vitamin
 B-complex, other B-vitamins, **vitamin C**, fat soluble
 vitamin, **bioflavonoid**, carotenoid, phytoestrogen, Coenzyme 10
 and N-acetyl cysteine.

DETAILED DESCRIPTION - A multi-vitamin and mineral combination (I)
 comprises: thiamin (a) (50-100 mg), riboflavin (b) (45-55 mg), niacin (c)
 (50-100 mg), vitamin B6 (d) (50-100 mg), folate (e) (400-800 micro g),
 vitamin B12 (f) (80-120 micro g), biotin (g) (80-220 micro g), pantothenic
 acid (h) (40-60 mg), choline (i) (40-60 mg), inositol (j) (40-60 mg),
 para-amino benzoic acid (k) (40-60 mg), **vitamin C** (l)
 (100-500 mg), calcium (m) (240-600 mg), magnesium (n) (120-275 mg), iodine
 (o) (120-180 micro g), selenium (p) (160-240 micro g), manganese (q)
 (0.8-1.2 mg), chromium (r) (200-800 micro g), molybdenum (s) (60-90 micro
 g), boron (t) (5-10 mg), zinc (u) (4.5-33 mg), potassium (v) (0.8-1.2 mg),

silicon (w) (1.6-2.4 mg), sulfur (x) (4-6 mg), vanadium (y) (8-12 mg), citrus bioflavonoid complex (z) (32-48 mg), hesperidin complex (aa) (3.2-4.8 mg), rutin (bb) (32-48 mg), vitamin A (cc) (15000-25000 IU), vitamin D (dd) (320-480 IU), vitamin E (ee) (400-880 IU), lycopene (ff) (4-6 mg), lutein (gg) (4.8-7.2 mg), Coenzyme Q10 (hh) (15-60 mg) and N-acetyl cysteine (ii) (540-660 mg).

An INDEPENDENT CLAIM is also included for a multi-vitamin and mineral combination (II) comprising (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) (540-660 mg), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (bb), (cc), (dd), (ee), (ff), (gg), (hh) and alpha-lipoic acid (ii) (90-100 mg).

ACTIVITY - Antiasthmatic; Antidiabetic.

MECHANISM OF ACTION - None given.

USE - For supplementing nutritional intake of humans with asthma and diabetes; in the adjunct care of asthma and/or diabetes (claimed).

ADVANTAGE - The formulation is high-potency that minimizes the number of dosages needed for optimal nutritional supplementation. The formulation reduces the risk of vitamin and mineral overdosing and toxicity.

Dwg.0/0

L27 ANSWER 2 OF 13 MEDLINE
 ACCESSION NUMBER: 2002432863 MEDLINE
 DOCUMENT NUMBER: 22141975 PubMed ID: 12147447
 TITLE: [Vitamins and aging].
 Vitamines et vieillissement.
 AUTHOR: Birlouez I; Cals M J; Covi G; Dauvergne A; Faure H; Fayol V; Galabert C; Gueant J L; Guillard J C; Herbeth B; Herberg S; Jardel A; Jeandel C; Leger C; Le Moel G; Lemoine A; Rousselot D; Therond P; Vidailhet M
 SOURCE: ANNALES DE BIOLOGIE CLINIQUE, (2002 Jul-Aug) 60 (4) 429-41.
 Journal code: 2984690R. ISSN: 0003-3898.
 PUB. COUNTRY: France
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: French
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200209
 ENTRY DATE: Entered STN: 20020823
 Last Updated on STN: 20020928
 Entered Medline: 20020927

L27 ANSWER 3 OF 13 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2002437790 EMBASE
 TITLE: Natural health product use in Canada.
 AUTHOR: Tropmann L.; Johns T.; Gray-Donald K.
 CORPORATE SOURCE: Dr. T. Johns, School of Dietetics/Human Nutrition, McGill University, 21 111 Lakeshore Road, Ste. Anne de Bellevue, Que. H9X 3V9, Canada. johns@macdonald.mcgill.ca
 SOURCE: Canadian Journal of Public Health, (2002) 93/6 (426-430).
 Refs: 36
 ISSN: 0008-4263 CODEN: CJPEA4
 COUNTRY: Canada
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English; French
 AB Objective: To quantify patterns of Natural Health Product (NHP) use in Canada. Methods: The Food Habits of Canadians surveyed 1,543 Canadian

adults using a 24-hour recall to record dietary supplements. Prevalence of use by user profile was examined. Results: Forty-six percent of women and 33% of men reported taking at least one Natural Health Product with a mean of 2.3 among users. The highest prevalence of supplement use, 57%, occurred among women aged 50-65. Supplement users were older, less likely to smoke and perceived their health as better than non-users. Among supplement users, men had higher rates of use of garlic and **vitamin C** while women used iron, calcium, B complex, evening primrose oil and glucosamine sulfate. Discussion: Supplement use by Canadians, at 38% for nutrients and 15% for herbal products, was similar to the rate of uses in the U.S., although differences in the reporting of types of supplements underline aspects of consumer behaviour as well as methodological issues specific to NHPs. Investigation of the use of NHPs in the healthcare setting is important given the widespread use and the potential health care consequences associated with supplement use.

L27 ANSWER 4 OF 13 WPIDS (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 2001-354884 [37] WPIDS
 DOC. NO. CPI: C2001-109868
 TITLE: Composition comprising a fatty acid, a calcium and a folic acid compound useful in meeting the nutritional need and maximizing the neurological maintenance of menopausal women and treating conditions associated with menopause.
 DERWENT CLASS: B05
 INVENTOR(S): HERMELIN, M S; KIRSCHNER, M I; LEVINSON, S R; LEVINSON, R S
 PATENT ASSIGNEE(S): (KVPH-N) KV PHARM CO; (DRUG-N) DRUGTECH CORP; (PHAR-N) PHARM TECHNOLOGY CORP; (DRUG-N) DRUG CORP
 COUNTRY COUNT: 95
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001024772	A1	20010412	(200137)*	EN	88
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2000069416	A	20010510	(200143)		
EP 1216024	A1	20020626	(200249)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
BR 2000014438	A	20020820	(200263)		
US 2002137749	A1	20020926	(200265)		
US 6479545	B1	20021112	(200278)		
US 2002173510	A1	20021121	(200279)		
KR 2002048424	A	20020622	(200281)		
JP 2003510344	W	20030318	(200321)		54
CN 1391464	A	20030115	(200330)		
ZA 2002002633	A	20030430	(200334)		93

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

WO 2001024772 A1	WO 2000-US23527	20000828
AU 2000069416 A	AU 2000-69416	20000828
EP 1216024 A1	EP 2000-957857	20000828
	WO 2000-US23527	20000828
BR 2000014438 A	BR 2000-14438	20000828
	WO 2000-US23527	20000828
US 2002137749 A1 Div ex	US 1999-409059	19990930
	US 2002-106381	20020327
US 6479545 B1	US 1999-409059	19990930
US 2002173510 A1 Cont of	US 1999-409059	19990930
	US 2002-131236	20020425
KR 2002048424 A	KR 2002-704093	20020329
JP 2003510344 W	WO 2000-US23527	20000828
	JP 2001-527771	20000828
CN 1391464 A	CN 2000-815270	20000828
ZA 2002002633 A	ZA 2002-2633	20020404

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000069416 A	Based on	WO 200124772
EP 1216024 A1	Based on	WO 200124772
BR 2000014438 A	Based on	WO 200124772
JP 2003510344 W	Based on	WO 200124772

PRIORITY APPLN. INFO: US 1999-409059 19990930; US 2002-106381
20020327; US 2002-131236 20020425

AN 2001-354884 [37] WPIDS

AB WO 200124772 A UPAB: 20010704

NOVELTY - Composition for administration to menopausal and pre-menopausal women comprising an essential fatty acid, a calcium compound and a folic acid compound is new.

DETAILED DESCRIPTION - A composition for administration to menopausal and pre-menopausal women comprises an essential fatty acid selected from linoleic acid, linolenic acid compound, a docosahexaenoic acid, an omega-3 fatty acid compound and/or an omega-2 fatty acid compound in an amount of 10-1000 mg, a calcium compound or derivative in an amount of 400-2500 mg, a folic acid compound or derivative in an amount of 0.4-5.0 mg. The weight ratio of the essential fatty acid compound to the calcium compound or derivative is 1:0.4-250.

INDEPENDENT CLAIMS are included for:

(a) a composition for administration to a menopausal women comprises a first fatty acid selected from a linoleic acid compound and/or derivative in an amount of 10-1000 mg, a second fatty acid selected from a linolenic acid compound in an amount of 10-1000 mg, a third fatty acid selected from a docosahexaenoic acid, an omega-3 fatty acid compound and/or an omega-2 fatty acid compound in an amount of 10-1000 mg, a calcium compound or derivative in an amount of 400-2500 mg, a folic acid compound or derivative in an amount of 0.4-5.0 mg, a vitamin C compound or derivative in an amount of 25-500 mg, a vitamin E compound or derivative in an amount of 10-500 mg. The weight ratio of the sum of the amounts of the first and second fatty acid compound to the amount of the third fatty acid compound is 1:0.4-1.5 and the weight ratio of the sum of the amounts of the first, second and third fatty acid compound to the calcium compound or derivative is 1:0.4-50.

(b) a composition as in (a) above, and further comprising a

vitamin A compound or derivative of 2,500-6,500 IU;

(c) a composition as in (a) above, and further comprising a vitamin B6 compound of 10-50 mg, a vitamin B12 compound or derivative of 25-75 mcg, a **vitamin D** compound or derivative of 200-625 IU;

(d) a composition for administration to a menopausal woman comprising a substance for treating symptoms of menopause, a calcium compound or derivative in an amount of 400-2500 mg, and a folic acid compound or derivative in an amount of 0.4-5.0 mg;

(e) a drug delivery regimen comprising a first dosage form comprising a first substance to be administered to a menopausal woman at a pre-determined time period, a second dosage form comprising a second substance to be administered simultaneously with the first dosage form; the first substance and the second substance are incompatible;

(f) a method for providing nutritional supplementation to a pre-menopausal or menopausal woman while reducing symptoms associated with menopause;

(g) a method of delaying the onset of menopause; and

(h) a method of reducing the possibility of premature menopause.

ACTIVITY - Gynecological.

MECHANISM OF ACTION - None given.

USE - The compound is useful in meeting the nutritional need and maximizing the neurological maintenance of menopausal women and treating conditions associated with menopause. (claimed)

ADVANTAGE - The compositions contain critical components specifically tailored to meet the need of pre-menopausal and menopausal women.
Dwg.0/0

L27 ANSWER 5 OF 13 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2001156944 EMBASE
TITLE: Polymorphic ventricular tachycardia in a woman taking cesium chloride.
AUTHOR: Saliba W.; Erdogan O.; Niebauer M.
CORPORATE SOURCE: Dr. W. Saliba, Dept. of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, United States. salibaw@ccf.org
SOURCE: PACE - Pacing and Clinical Electrophysiology, (2001) 24/4 I (515-517).
Refs: 10
ISSN: 0147-8389 CODEN: PPCEDP
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
024 Anesthesiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB A 47-year-old patient presented with syncope and recurrent episodes of polymorphic ventricular tachycardia. She had evidence of prolonged QT interval by ECG and had been taking cesium as a dietary supplement. Correction of the hypokalemia and discontinuation of the cesium resulted in normalization of the QT interval during follow-up with no further recurrence of ventricular arrhythmias. The use of this drug is potentially hazardous as it may induce fatal ventricular arrhythmias.

L27 ANSWER 6 OF 13 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2001241085 EMBASE

TITLE: Micro-nutrient supplementation and the intelligence of children.
 AUTHOR: Benton D.
 CORPORATE SOURCE: D. Benton, Department of Psychology, University of Wales Swansea, Swansea SA2 8PP, United Kingdom.
 d.benton@swansea.ac.uk
 SOURCE: Neuroscience and Biobehavioral Reviews, (2001) 25/4 (297-309).
 Refs: 76
 ISSN: 0149-7634 CODEN: NBREDE
 PUBLISHER IDENT.: S 0149-7634(01)00015-X
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
 032 Psychiatry
 007 Pediatrics and Pediatric Surgery
 008 Neurology and Neurosurgery
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB A growing number of double-blind placebo-controlled studies have considered the influence of micro-nutrient supplementation on the intelligence of children. Earlier studies prevented the drawing of conclusions as they did not systematically approach the topic. However, over the last 10 years, a series of studies have compared the impact of supplementation on either verbal or non-verbal measures of intelligence. In 10 out of 13 studies a positive response has been reported, always with non-verbal measures, in at least a sub-section of the experimental sample. A selective response to non-verbal tests was predicted as they reflect basic biologically functioning that could be expected to be influenced by diet. The evidence is that not all children respond to supplementation, rather there is a minority who benefit, whose diet offers low amounts of micro-nutrients. Such observations are consistent with dietary surveys that typically report a sub-set of children with a low intake. The topic is at a very early stage and needs the clarification gained from a series of large-scale studies that consider children of a wide range of ages, dietary styles and social backgrounds. Copyright .COPYRGT. 2001 Elsevier Science Ltd.

L27 ANSWER 7 OF 13 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2000115165 EMBASE
 TITLE: [What do we know about the diet of patients with oncological diseases?].
 CO VIME O VYZIVE U PACIENTU S ONKOLOGICKYM ONEMOCNENIM?.
 AUTHOR: Markova J.; Vyzula R.
 CORPORATE SOURCE: Dr. J. Markova, Univerzitetni Onkologicke Centrum, Fakultni Nemocnice, Jihlavská 20, 639 00 Brno, Czech Republic
 SOURCE: Prakticky Lekar, (25 Mar 2000) 80/3 (149-152).
 Refs: 21
 ISSN: 0032-6739 CODEN: PRLEAD
 COUNTRY: Czech Republic
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 016 Cancer
 029 Clinical Biochemistry
 LANGUAGE: Czech
 SUMMARY LANGUAGE: English; Czech
 AB The authors present a review on the character of the diet and prevention of malnutrition in oncological patients. By rational application of dietary intervention during treatment of a malignant disease it is

possible to improve the tolerance of treatment and quality of life of these patients. The authors summarize the basic objectives of the dietary regimen. In addition to different nutrients the authors present also nutritional recommendations in case of undesirable effects of chemotherapy. The paper deals also briefly with alternate dietetic procedures. The diet is non-toxic, economically feasible and scientifically supportive treatment of oncological diseases.

L27 ANSWER 8 OF 13 WPIDS (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 1997-279778 [25] WPIDS
 DOC. NO. CPI: C1997-089883
 TITLE: Treatment and prevention of sickle cell crisis -
 comprises administration of vitamin, mineral and
 micronutrient formulations as sustained release
 compositions.
 DERWENT CLASS: B05
 INVENTOR(S): LOCKETT, C G; LOCKETT, C
 PATENT ASSIGNEE(S): (LOCK-I) LOCKETT C G; (LOCK-I) LOCKETT C
 COUNTRY COUNT: 75
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 5626884	A	19970506	(199725)*		5
WO 9850051	A1	19981112	(199851)#	EN	
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN					
AU 9729932	A	19981127	(199915)#		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5626884	A	US 1995-516737	19950818
WO 9850051	A1	WO 1997-US7122	19970505
AU 9729932	A	AU 1997-29932	19970505
		WO 1997-US7122	19970505

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9729932	A Based on	WO 9850051

PRIORITY APPLN. INFO: US 1995-516737 19950818; WO 1997-US7122
 19970505; AU 1997-29932 19970505

AN 1997-279778 [25] WPIDS

AB US 5626884 A UPAB: 19970619

Treating or preventing sickle cell crisis in a person having sickle cell disease comprises administering a cumulative daily dosage of
vitamin A (8250-250000 I.U.), vitamin B-1 (25-1000 mg),
 vitamin B-2 (25-1000 mg), vitamin B-6 (25-1000 mg), **vitamin**
C (25-1000 mg), niacinamide (25-1000 mg), para-aminobenzoic acid
 (25-1000 mg), pantothenic acid (25-1000 mg), choline bitartrate (25-1000
 mg), inositol (25-1000 mu g), vitamin B-12 (25-1000 mu g), biotin (25-1000

mu g), **vitamin D** (100-4000 I.U.), folic acid (100-4000 mu g), **vitamin E** (25-1000 I.U.), rutin (8.25-250 mg), citrus **bioflavonoid** complex (8.25-250 mg), betaine hydrochloride (8.25-250 mg), iron (8.25-250 mg), hesperidin complex (1.25-50 mg), calcium (10-400 mg), magnesium (5-100 mg), zinc (5-100 mg), potassium (3.75-150 mg), manganese (1.5-60 mg), iodine (37.5-1500 mu g), chromium (3.75-150 mu g) and selenium (2.5-100 mu g).

ADVANTAGE - The medication may be administered outside a critical care environment. This allows persons suffering from sickle cell disease to lead more productive, normal lives. The constant threat of crisis onset is dramatically reduced, which contributes to greater mental and emotional confidence.

Dwg.0/0

L27 ANSWER 9 OF 13 MEDLINE
 ACCESSION NUMBER: 85243058 MEDLINE
 DOCUMENT NUMBER: 85243058 PubMed ID: 2861612
 TITLE: Role of selected nutrients in synthesis, accumulation, and chemical modification of connective tissue proteins.
 AUTHOR: Tinker D; Rucker R B
 CONTRACT NUMBER: AM-25358 (NIADDK)
 HL-15965 (NHLBI)
 SOURCE: PHYSIOLOGICAL REVIEWS, (1985 Jul) 65 (3) 607-57. Ref: 453
 Journal code: 0231714. ISSN: 0031-9333.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198508
 ENTRY DATE: Entered STN: 19900320
 Last Updated on STN: 19970203
 Entered Medline: 19850816

L27 ANSWER 10 OF 13 MEDLINE
 ACCESSION NUMBER: 80192385 MEDLINE
 DOCUMENT NUMBER: 80192385 PubMed ID: 6445605
 TITLE: [Vitamins in the immune response].
 Vitaminy v immunnom otvete.
 AUTHOR: Pletsityi K D
 SOURCE: TERAPEVTICHESKII ARKHIV, (1980) 52 (2) 131-40. Ref: 127
 Journal code: 2984818R. ISSN: 0040-3660.
 PUB. COUNTRY: USSR
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: Russian
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198007
 ENTRY DATE: Entered STN: 19900315
 Last Updated on STN: 19900315
 Entered Medline: 19800712

L27 ANSWER 11 OF 13 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 75035406 EMBASE
 DOCUMENT NUMBER: 1975035406
 TITLE: [Enzymes, hormones and vitamins and their interrelationships. Vol. III/1 Vitamins].
 FERMENTE, HORMONE, VITAMINE, UND DIE BEZIEHUNGEN DIESER

WIRKSTOFFE ZUEINANDER: BAND III/1 VITAMINE.

AUTHOR: Ammon R.; Dirscherl W.
 CORPORATE SOURCE: Physiol.-Chem. Inst., Univ. Saarland, 6650 Homburg/Saar, Germany
 SOURCE: (1974) (1000 p.) DM 348/-.
 DOCUMENT TYPE: Book
 FILE SEGMENT: 030 Pharmacology
 LANGUAGE: German

AB A review is given of vitamins and vitamin like substances. Attention is paid to the history of their discovery, to the chemistry in relation to their synthesis and biosynthesis, vitamin deficiencies, hypervitaminosis symptoms, biological actions, metabolism and therapeutic use. The question of antivitamin and methods of determination of the individual vitamins are also discussed.

L27 ANSWER 12 OF 13 MEDLINE

ACCESSION NUMBER: 73154408 MEDLINE
 DOCUMENT NUMBER: 73154408 PubMed ID: 4266745
 TITLE: [Vitamin therapy in ophthalmology].
 Vitaminoterapiia v oftal'mologii.
 AUTHOR: Margolis M G
 SOURCE: OFTALMOLOGICHESKII ZHURNAL, (1972) 27 (8) 624-30. Ref: 0
 Journal code: 0401105. ISSN: 0030-0675.
 PUB. COUNTRY: USSR
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: Russian
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 197306
 ENTRY DATE: Entered STN: 19900310
 Last Updated on STN: 19900310
 Entered Medline: 19730607

L27 ANSWER 13 OF 13 MEDLINE

ACCESSION NUMBER: 69162841 MEDLINE
 DOCUMENT NUMBER: 69162841 PubMed ID: 4238304
 TITLE: [Photometry in analysis of biologically highly active pharmaceutical preparations. 2].
 Fotometriia v analize biologicheskii vysokoaktivnykh farmatsevticheskikh preparatov. 2.
 AUTHOR: Aliev A M
 SOURCE: FARMATSIIA, (1967 Nov-Dec) 16 (6) 66-71. Ref: 147
 Journal code: 0136541. ISSN: 0367-3014.
 PUB. COUNTRY: USSR
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: Russian
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 196906
 ENTRY DATE: Entered STN: 19900101
 Last Updated on STN: 19900101
 Entered Medline: 19690602

WEST Search History

DATE: Friday, May 30, 2003

Set Name Query side by side

Hit Count Set Name result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L13	L11 and (L\$1ascorb\$4 or ascorbic or ascorbate or ascorbic acid or carotene or beta\$1carotene or \$2carotene or ergosterol or ergocalciferol or cholecalciferol)	11	L13
-----	--	----	-----

L12	L11 and (vitamin A or vitamin C or vitamin D)	11	L12
-----	---	----	-----

L11	zinc monomethionine	17	L11
-----	---------------------	----	-----

DB=USPT,PGPB; PLUR=YES; OP=ADJ

L10	zinc monomethionine	14	L10
-----	---------------------	----	-----

L9	us-5514382-\$.did.	1	L9
----	--------------------	---	----

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L8	wo-9850051-\$.did. or wo-9808522-\$.did.	4	L8
----	--	---	----

L7	wo-9850050-\$.did.	2	L7
----	--------------------	---	----

L6	wo-2001037829-\$.did.	0	L6
----	-----------------------	---	----

DB=USPT,PGPB; PLUR=YES; OP=ADJ

L5	us-6511675-\$.did.	1	L5
----	--------------------	---	----

L4	us-2002155163-\$.did.	0	L4
----	-----------------------	---	----

L3	us-2002155163-\$.did.	0	L3
----	-----------------------	---	----

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L2	us-2002155163-\$.did.	0	L2
----	-----------------------	---	----

L1	gb-2370504-\$.did.	2	L1
----	--------------------	---	----

END OF SEARCH HISTORY